Literature DB >> 3143425

Superovulation of immature rats by continuous infusion of follicle-stimulating hormone.

D T Armstrong1, M A Opavsky.   

Abstract

Immature female rats were infused s.c. continuously over a 60-h period with partially purified porcine pituitary follicle-stimulating hormone (FSH) preparations differing in degree of purity and having widely divergent luteinizing hormone (LH):FSH potency ratios as defined by radioreceptor assays. Rats infused with the more purified FSH preparation (FSH-A) ovulated a mean of 60-85 oocytes per rat on the morning of the third day (Day 1) after FSH infusion was begun (on Day -2). The same total dose of FSH administered as a single s.c. injection or as twice daily injections over the same 60-h period resulted in ovulation in only a minority of treated rats (3/16), with none achieving ovulation rates approaching those of rats infused continuously. High fertilization rates (80% of ovulated oocytes) were observed in superovulated rats joined with fertile males on the evening of the second day of infusion (Day 0). Of the 67 +/- 7 fertilized ova per rat retrieved from oviducts flushed on Day 1, 52 +/- 8, or 80%, were accounted for as morulae or blastocysts recovered when oviducts and uteri were flushed on the morning of Day 5, demonstrating essentially normal developmental rates and high survival rates in reproductive tracts of superovulated females during the preimplantation period. Infusion of rats with the same dose of a less well-purified FSH preparation (FSH-E) containing 20 times as much LH activity, or injection of rats with a superovulatory dose of pregnant mare's serum gonadotropin (PMSG) (40 IU), were much less effective in causing superovulation, with ovulation rates of 17 +/- 6 and 34 +/- 8 oocytes/rat, respectively, compared to 79 +/- 9 oocytes/rat infused with the FSH preparation (FSH-A) containing lower LH activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143425     DOI: 10.1095/biolreprod39.3.511

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  9 in total

1.  Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats.

Authors:  B R Davies; A M Platt-Higgins; G Schmidt; P S Rudland
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

Review 2.  Transgenesis in rats: technical aspects and models.

Authors:  B Charreau; L Tesson; J P Soulillou; C Pourcel; I Anegon
Journal:  Transgenic Res       Date:  1996-07       Impact factor: 2.788

3.  Advances in transgenic rat production.

Authors:  Wanda E Filipiak; Thomas L Saunders
Journal:  Transgenic Res       Date:  2006-09-29       Impact factor: 2.788

4.  Gene imprinting and major histocompatibility complex class I antigen expression in the rat placenta.

Authors:  A Kanbour-Shakir; X Zhang; A Rouleau; D T Armstrong; H W Kunz; T A Macpherson; T J Gill
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 5.  Nuclear transfer in rodents.

Authors:  Linda J Mullins; Ian Wilmut; John J Mullins
Journal:  J Physiol       Date:  2004-01-01       Impact factor: 5.182

6.  Development of a novel transgenic rat overexpressing the P2Y(2) nucleotide receptor using a lentiviral vector.

Authors:  Cansu Agca; Cheikh Seye; Corinna M Kashuba Benson; Shivaji Rikka; Anthony W S Chan; Gary A Weisman; Yuksel Agca
Journal:  J Vasc Res       Date:  2009-01-21       Impact factor: 1.934

Review 7.  From engineering to editing the rat genome.

Authors:  Stephen Meek; Tomoji Mashimo; Tom Burdon
Journal:  Mamm Genome       Date:  2017-07-27       Impact factor: 2.957

8.  Ovarian Follicular Growth through Intermittent Vaginal Gonadotropin Administration in Diminished Ovarian Reserve Women.

Authors:  Chao-Chin Hsu; Isabel Hsu; Li-Hsuan Lee; Rosie Hsu; Yuan-Shuo Hsueh; Chih-Ying Lin; Hui Hua Chang
Journal:  Pharmaceutics       Date:  2022-04-15       Impact factor: 6.525

9.  Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are regulated tissue-specifically.

Authors:  Cansu Agca; Jason J Fritz; Lary C Walker; Allan I Levey; Anthony Ws Chan; James J Lah; Yuksel Agca
Journal:  BMC Neurosci       Date:  2008-02-26       Impact factor: 3.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.